Global Acute Lymphocytic Leukemia Therapeutics Market

Description

Market Overview

The Global Acute Lymphocytic Leukemia Therapeutics Market size reached US$ 2.9 billion in 2022 and is expected to reach US$ 4.5 billion by 2030 and is expected to grow with a CAGR of 5.8% during the forecast period 2023-2030. Increasing leukemia in children and the growing clinical trials for novel drugs are driving up demand for acute lymphocytic leukemia therapeutics market trends.

B or T lymphoblasts malignancy is known as Acute lymphocytic leukemia (ALL) that is characterized by unchecked proliferation of immature, abnormal lymphocytes and their progenitors. This process eventually results in the replacement of bone marrow components and other lymphoid organs, producing a distinctive disease pattern.

The acute lymphocytic leukemia therapeutics market scope comprises therapy as Targeted Drugs & Immunotherapy, Radiation Therapy, Chemotherapy and Stem Cell Transplantation, which has increased the acute lymphocytic leukemia therapeutics market share. The global market for acute lymphocytic leukemia therapeutics is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the acute lymphocytic leukemia therapeutics market growth.

Market Dynamics

An Increase in the Incidence of Acute Lymphocytic Leukemia Drives the Growth of the Acute Lymphocytic Leukemia Therapeutics Market

The primary driver of this market's expansion globally is the increasing incidence of acute lymphocytic leukemia (ALL). Approximately 1.7 new cases per 100,000 men and women are reported annually. According to projections from the American Cancer Society, there will be approximately 6,540 new instances of acute lymphocytic leukemia (ALL) in the country in 2023 (including kids and adults), comprising 3,660 male cases and 2,880 female cases and approximately 1,390 ALL-related deaths, including 700 male cases and 690 female cases.

Children under the age of 5 have the highest chance of developing ALL. The risk then gradually decreases until the mid-20s and then slowly starts to increase again around age 50. Hence, the growing cases of lymphocytic leukemia are driving the acute lymphocytic leukemia therapeutics market.

Rising Research and Development Creates Lucrative Opportunities for Manufacturers

Various developments are being done by the researchers that will provide future insight and will provide a better approach to treatment. For instance, researchers hoped to learn more about the characteristics of self-renewing leukemia-initiating cells to better understand how they cause high-risk B-ALL to relapse. To determine which genes these cells were activating at different times, they utilized single-cell RNA sequencing in conjunction with transplant studies to examine the cells' growth.

The leukemia was found to be controlled by suppressing glycolysis and hypoxia signaling in leukemia-initiating cells when they were dormant. In the process of being driven back to the oxidative phosphorylation nation, the cells lost their ability to cause leukemia. Thus these factors will create an opportunity for the growth of the acute lymphocytic leukemia therapeutics market size.

Complications Associated With the Treatment Will Hamper the Growth of the Market

Although supportive care has improved, it is still difficult to prevent death brought on by treatment toxicity. Tumor Lysis Syndrome, which happens when chemotherapy induces cancer cells to lyse and release certain internal elements like potassium, uric acid, calcium and phosphorus, should be kept an eye out for. These substances produce toxicity when present in high concentrations, which frequently results in renal failure.

Tumor Lysis Syndrome is often avoided by pretreatment with fluids and steroids. But if it does, the remedy is intensive fluid therapy. Acute lymphocytic leukemia might return even after treatment. Relapses might happen up to 21 years past. It is crucial to address additional concerns related to a young kid's cancer treatment, such as giving the kid, their parents and their family psychological support.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global acute lymphocytic leukemia therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global acute lymphocytic leukemia therapeutics market growth over the forecast period.

Segment Analysis

The global acute lymphocytic leukemia therapeutics market is segmented based on treatment type, therapy, cell type, distribution channel and region.

Philadelphia Chromosome From Cell Type Segment Accounts for 40.3% of Market Share Owing to Rising Novel Product Launches

Acute lymphoblastic leukemia (ALL), which has the Philadelphia chromosome (Ph+ ), makes up around one-fourth of adult ALL cases. It often has an aggressive clinical course, does not react well to conventional chemotherapy and is highly plausible. Ph+ ALL is a rapidly developing condition for which there are presently no front-line targeted therapies authorized in the United States.

A potent therapy that can prevent the emergence of challenging-to-treat mutations, which are linked to suboptimal long-term results, is urgently required. Since the invention of tyrosine kinase inhibitors (TKIs), the landscape of Ph+ ALL therapy has improved. The PhALLCON study compares ICLUSIG and imatinib in combination with low-intensity chemotherapy as a primary therapy for adult patients having newly diagnosed Ph+ ALL. It is a Phase 3 randomized, multinational, open-label multicenter experiment.

Geographical Analysis

North America Accounted For Approximately 41.3% Of the Market Share Owing to The Strong Presence Of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for acute lymphocytic leukemia therapeutics for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of acute lymphocytic leukemia therapeutics, which has increased the demand.

Rising new drugs for different types of lymphocytic leukemia will drive the market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of treatment approaches for acute lymphocytic leukemia, leading to the expansion of the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the acute lymphocytic leukemia therapeutics market include: Merck & Co. Inc., Pfizer Inc., Bristol-Myers Squibb, Novartis AG, Takeda Pharmaceutical Company Limited, Sanofi, Spectrum Pharmaceuticals, Inc., Rare Disease Therapeutics, Inc., SymBio Pharmaceuticals Limited and Erytech Pharma among others.

Why Purchase the Report?

To visualize the global acute lymphocytic leukemia therapeutics market segmentation based on treatment type, therapy, cell type, distribution channel and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of acute lymphocytic leukemia therapeutics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Acute Lymphocytic Leukemia Therapeutics Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2023

Manufacturers / Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

Product Code: PH2878

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Treatment Type
3.2. Snippet by Therapy
3.3. Snippet by Cell Type
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Initiatives Taken by the Government and Private Organizations
  - 4.1.1.2. The Growing Incidence of Acute Lymphocytic Leukemia
- 4.1.2. Restraints
  - 4.1.2.1. Complications Associated with the Treatment
- 4.1.3. Opportunity
  - 4.1.3.1. Rising Research and Development
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Treatment Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drugs
- 7.2.1. Pegasparaginase (Oncaspar) *
  - 7.2.1.1. Introduction
  - 7.2.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.2. Cyclophosphamide (Neosar)
- 7.2.3. Daunorubicin (Cerubidine)
- 7.2.4. Doxorubicin (Adriamycin)
- 7.2.5. Nelarabine (Arranon)
- 7.2.6. Rituximab (Rituxan)
- 7.2.7. Nilotinib (Tasigna)
- 7.2.8. Others
7.3. Surgery
7.4. Others

8. By Therapy

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 8.1.2. Market Attractiveness Index, By Therapy
8.2. Targeted Drugs & Immunotherapy *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Radiation Therapy
8.4. Chemotherapy
8.5. Stem Cell Transplantation

9. By Cell Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 9.1.2. Market Attractiveness Index, By Cell Type
9.2. Philadelphia Chromosome *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Precursor B-Cell ALL
9.4. T-Cell ALL

10. By End user

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospital & Hospital Pharmacy *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Radiation Therapy and Online Pharmacy
10.4. Ambulatory Surgical Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. The U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. The U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan

Australia

11.5.7.4. Rest of Asia-Pacific

11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Amgen Inc. *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Bristol-Myers Squibb
13.3. Pfizer Inc.
13.4. Novartis AG
13.5. Sanofi
13.6. Takeda Pharmaceutical Company Limited
13.7. Spectrum Pharmaceuticals, Inc.
13.8. SymBio Pharmaceuticals Limited
13.9. Rare Disease Therapeutics, Inc.
13.10. Erytech Pharma

LIST NOT EXHAUSTIVE

14. Appendix

14.1. About Us and Services
14.2. Contact Us

Global Acute Lymphocytic Leukemia Therapeutics Market - 2023-2030